Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
Hodgkin lymphoma (HL) is a B-cell malignancy representing approximately one in ten lymphomas diagnosed in the United States annually. The majority of patients with HL can be cured with chemotherapy; however, 5–10% will have refractory disease to front-line therapy and 10–30% will relapse. For those...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-10-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/10/2887 |
id |
doaj-251f5831ff964ce6b104063f1eab3f1f |
---|---|
record_format |
Article |
spelling |
doaj-251f5831ff964ce6b104063f1eab3f1f2020-11-25T03:43:15ZengMDPI AGCancers2072-66942020-10-01122887288710.3390/cancers12102887Therapeutic Updates for Relapsed and Refractory Classical Hodgkin LymphomaTimothy J Voorhees0Anne W Beaven1Department of Internal Medicine, Division of Hematology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27514, USADepartment of Internal Medicine, Division of Hematology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27514, USAHodgkin lymphoma (HL) is a B-cell malignancy representing approximately one in ten lymphomas diagnosed in the United States annually. The majority of patients with HL can be cured with chemotherapy; however, 5–10% will have refractory disease to front-line therapy and 10–30% will relapse. For those with relapsed or refractory (r/r) HL, salvage chemotherapy followed by autologous stem cell transplant (ASCT) is standard of care, but half of patients will subsequently have disease progression. Relapse following ASCT has been associated with exceedingly poor prognosis with a median survival of only 26 months. However, in recent years, novel agents including brentuximab vedotin (BV) and programmed cell death protein 1 monoclonal antibodies (anti-PD-1, nivolumab and pembrolizumab) have been shown to extend overall survival in r/r HL. With the success of novel agents in relapsed disease after ASCT, these therapies are beginning to show clinically meaningful response rates prior to ASCT. Finally, a new investigation in r/r HL continues to produce promising treatment options even after ASCT including CD30 directed chimeric antigen receptor T-cell therapy. In this review, we will discuss the recent advances of BV and anti-PD-1 therapy prior to ASCT, novel approaches in r/r HL after ASCT, and review active clinical trials.https://www.mdpi.com/2072-6694/12/10/2887Hodgkin lymphomabrentuximab vedotinnivolumabpembrolizumabsalvage therapynovel therapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Timothy J Voorhees Anne W Beaven |
spellingShingle |
Timothy J Voorhees Anne W Beaven Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma Cancers Hodgkin lymphoma brentuximab vedotin nivolumab pembrolizumab salvage therapy novel therapy |
author_facet |
Timothy J Voorhees Anne W Beaven |
author_sort |
Timothy J Voorhees |
title |
Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma |
title_short |
Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma |
title_full |
Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma |
title_fullStr |
Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma |
title_full_unstemmed |
Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma |
title_sort |
therapeutic updates for relapsed and refractory classical hodgkin lymphoma |
publisher |
MDPI AG |
series |
Cancers |
issn |
2072-6694 |
publishDate |
2020-10-01 |
description |
Hodgkin lymphoma (HL) is a B-cell malignancy representing approximately one in ten lymphomas diagnosed in the United States annually. The majority of patients with HL can be cured with chemotherapy; however, 5–10% will have refractory disease to front-line therapy and 10–30% will relapse. For those with relapsed or refractory (r/r) HL, salvage chemotherapy followed by autologous stem cell transplant (ASCT) is standard of care, but half of patients will subsequently have disease progression. Relapse following ASCT has been associated with exceedingly poor prognosis with a median survival of only 26 months. However, in recent years, novel agents including brentuximab vedotin (BV) and programmed cell death protein 1 monoclonal antibodies (anti-PD-1, nivolumab and pembrolizumab) have been shown to extend overall survival in r/r HL. With the success of novel agents in relapsed disease after ASCT, these therapies are beginning to show clinically meaningful response rates prior to ASCT. Finally, a new investigation in r/r HL continues to produce promising treatment options even after ASCT including CD30 directed chimeric antigen receptor T-cell therapy. In this review, we will discuss the recent advances of BV and anti-PD-1 therapy prior to ASCT, novel approaches in r/r HL after ASCT, and review active clinical trials. |
topic |
Hodgkin lymphoma brentuximab vedotin nivolumab pembrolizumab salvage therapy novel therapy |
url |
https://www.mdpi.com/2072-6694/12/10/2887 |
work_keys_str_mv |
AT timothyjvoorhees therapeuticupdatesforrelapsedandrefractoryclassicalhodgkinlymphoma AT annewbeaven therapeuticupdatesforrelapsedandrefractoryclassicalhodgkinlymphoma |
_version_ |
1724521095937130496 |